An update on immunotherapy with PD-1 and PD-L1 blockade
Open Access
- 31 October 2021
- journal article
- Published by Yeungnam University College of Medicine in Journal of Yeungnam Medical Science
- Vol. 38 (4), 308-317
- https://doi.org/10.12701/yujm.2021.01312
Abstract
Cancer is the leading cause of death and is on the rise worldwide. Until 2010, the development of targeted treatment was mainly focused on the growth mechanisms of cancer. Since then, drugs with mechanisms related to tumor immunity, especially immune checkpoint inhibitors, have proven effective, and most pharmaceutical companies are striving to develop related drugs. Programmed cell death-1 and programmed cell death ligand-1 inhibitors have shown great success in various cancer types. They showed durable and sustainable responses and were approved by the U.S. Food and Drug Administration. However, the response to inhibitors showed low percentages of cancer patients; 15% to 20%. Therefore, combination strategies with immunotherapy and conventional treatments were used to overcome the low response rate. Studies on combination therapy have typically reported improvements in the response rate and efficacy in several cancers, including non-small cell lung cancer, small cell lung cancer, breast cancer, and urogenital cancers. The combination of chemotherapy or targeted agents with immunotherapy is one of the leading pathways for cancer treatment.Keywords
This publication has 65 references indexed in Scilit:
- Incorporating Immune-Checkpoint Inhibitors into Systemic Therapy of NSCLCJournal of Thoracic Oncology, 2014
- Natural Innate and Adaptive Immunity to CancerAnnual Review of Immunology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- PD-L1 regulates the development, maintenance, and function of induced regulatory T cellsThe Journal of Experimental Medicine, 2009
- CTLA-4 Control over Foxp3 + Regulatory T Cell FunctionScience, 2008
- Inhibitory B7-family molecules in the tumour microenvironmentNature Reviews Immunology, 2008
- Tumour immunity: effector response to tumour and role of the microenvironmentThe Lancet, 2008
- Checkpoint Blockade in Cancer ImmunotherapyAdvances in Immunology, 2006
- Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockadeProceedings of the National Academy of Sciences of the United States of America, 2002
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasionNature Medicine, 2002